Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?
On November 21, shares rose CRISPR therapeutics (NASDAQ: CRSB) Prices fell by 47% from their peak in March. This may be a bit surprising to people who follow this developer of gene therapies. After all, it's been less than a year!-->…